Multi-centre randomised controlled trial of symptomatic versus intensive bisphosphonate therapy for Paget's disease

Submission date	Recruitment status	Prospectively registered		
05/02/2002	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
05/02/2002	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
21/12/2023	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof SH Ralston

Contact details

University of Edinburgh, Molecular Medicine Centre Western General Hospital Crewe Road South Edinburgh United Kingdom EH4 2XU +44 (0)131 651 1037 / 1035 stuart.ralston@ed.ac.uk

Additional identifiers

Protocol serial number

ARC 13627

Study information

Scientific Title

Multi-centre randomised controlled trial of symptomatic versus intensive bisphosphonate therapy for Paget's disease

Acronym

PRISM

Study objectives

Intensive bisphosphonate therapy is superior to symptomatic management in the prevention of long-term complications associated with Paget's disease of bone

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multicentre randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Paget's disease

Interventions

Patients will be randomised to either symptomatic treatment or intensive treatment with a bisphosphonate to maintain serum alkaline phosphatase within the normal range

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Bisphosphonate

Primary outcome(s)

Fracture rate

Key secondary outcome(s))

- 1. Progression of hearing loss
- 2. Self-reported health related quality of life
- 3. Requirement for joint replacement

Completion date

Eligibility

Key inclusion criteria

The trial will involve patients with Paget's disease over the age of 18 years with symptomatic or asymptomatic disease receiving care at participating hospitals throughout the UK.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

1324

Key exclusion criteria

- 1. Under 18 years of age
- 2. Unable to provide written consent
- 3. Judged by clinician to be too ill or frail to participate
- 4. Life expectancy of less than one year

Date of first enrolment

01/12/2001

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

United Kingdom

Scotland

Study participating centre
University of Edinburgh, Molecular Medicine Centre
Edinburgh

Sponsor information

Organisation

University of Edinburgh and NHS Lothian (UK)

ROR

https://ror.org/03q82t418

Funder(s)

Funder type

Charity

Funder Name

Arthritis UK (previously Arthritis Research Campaign [ARC]) (UK)

Funder Name

Aventis & Procter & Gamble (UK)

Funder Name

National Association for Relief of Paget's Disease (NARPD) (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2010	Yes	No
Other publications	Genetic analysis of PRISM participants	01/11/2010 21/12/2023	Yes	No

Study website

Study website

11/11/2025 11/11/2025 No Yes